SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Zhong-Min Liu, Miao Hu, Paul Chan, Brian Tomlinson, Early investigational drugs targeting PPAR-α for the treatment of metabolic disease, Expert Opinion on Investigational Drugs, 2015, 1

    CrossRef

  2. 2
    B. Fromenty, Burn after feeding. An old uncoupler of oxidative phosphorylation is redesigned for the treatment of nonalcoholic fatty liver disease, Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 5, 545

    CrossRef

  3. 3
    Herbert Tilg, Alexander R Moschen, Evolving therapies for non-alcoholic steatohepatitis, Expert Opinion on Drug Discovery, 2014, 9, 6, 687

    CrossRef

  4. 4
    Bertrand Cariou, Bart Staels, GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes, Expert Opinion on Investigational Drugs, 2014, 23, 10, 1441

    CrossRef

  5. 5
    Fabio Marra, Angela Provenzano, Elisa Vivoli, Mechanisms of Fibrosis in Steatohepatitis, Current Hepatology Reports, 2014, 13, 2, 142

    CrossRef

  6. 6
    Michal Pawlak, Philippe Lefebvre, Bart Staels, Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease, Journal of Hepatology, 2014,

    CrossRef

  7. 7
    Amirhossein Sahebkar, Gerard T Chew, Gerald F Watts, New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease, Expert Opinion on Pharmacotherapy, 2014, 15, 4, 493

    CrossRef

  8. 8
    Sohrab Rahimi Naini, Michael Fuchs, Non-alcoholic fatty liver disease in patients with diabetes mellitus, Expert Review of Endocrinology & Metabolism, 2014, 9, 5, 503

    CrossRef

  9. 9
    Aaron M. Gusdon, Ke-xiu Song, Shen Qu, Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective, Oxidative Medicine and Cellular Longevity, 2014, 2014, 1

    CrossRef

  10. 10
    Amirhossein Sahebkar, Gerard T. Chew, Gerald F. Watts, Recent advances in pharmacotherapy for hypertriglyceridemia, Progress in Lipid Research, 2014, 56, 47

    CrossRef

  11. 11
    Nishika Sahini, Jürgen Borlak, Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes, Progress in Lipid Research, 2014, 54, 86

    CrossRef

  12. 12
    Claudia D. Fuchs, Thierry Claudel, Michael Trauner, Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD, Trends in Endocrinology & Metabolism, 2014, 25, 11, 576

    CrossRef

  13. 13
    A. Sahebkar, G. F. Watts, Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster, Diabetes, Obesity and Metabolism, 2014, 16, 9
  14. 14
    Pablo Quintero, Marco Arrese, Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism, Hepatology, 2013, 58, 6